People take Ozempic primarily to manage type 2 diabetes, but millions also use it (or its higher-dose sibling, Wegovy) for weight loss and heart protection. The drug is a once-weekly injection of semaglutide, which mimics a gut hormone called GLP-1 that your body naturally releases after eating. That single mechanism produces a surprisingly wide range of effects, from blood sugar control to reduced appetite to measurable protection against heart attacks and kidney disease.
How Ozempic Works in the Body
After you eat, your intestines release GLP-1, a hormone that signals your pancreas to produce insulin and tells your brain you’re full. The natural version is broken down by an enzyme within minutes. Semaglutide is engineered to resist that breakdown, so a single weekly injection keeps GLP-1 receptors activated for days.
That sustained activation does several things at once. It boosts insulin release (but only when blood sugar is elevated, which lowers the risk of dangerous blood sugar crashes). It suppresses glucagon, a hormone that raises blood sugar. It slows the rate at which your stomach empties food into the small intestine, which keeps you feeling full longer. And it acts on appetite centers in the brain, reducing cravings and the reward signals associated with eating.
Managing Type 2 Diabetes
The original and still primary FDA-approved use for Ozempic is improving blood sugar control in adults with type 2 diabetes. In real-world data, patients on the 1.0 mg weekly dose saw their HbA1c (a measure of average blood sugar over roughly three months) drop by 1.2 percentage points. Those who stayed on the medication consistently saw an even larger reduction of 1.4 points. For context, most diabetes guidelines consider a drop of 0.5 points clinically meaningful, so these are substantial improvements.
The starting dose of 0.25 mg isn’t actually therapeutic. It exists solely to let your body adjust and minimize side effects. After four weeks, the dose increases to 0.5 mg, then potentially up to a maximum of 2 mg depending on how well your blood sugar responds.
Weight Loss
Weight loss is the reason Ozempic became a household name, even though the brand itself is technically approved only for diabetes. Wegovy, which contains the same drug at a higher dose, is the version approved specifically for weight management in adults with obesity or those who are overweight with at least one weight-related health condition.
The weight loss comes from two directions. Slower stomach emptying means smaller portions feel satisfying. Meanwhile, the drug’s action in the brain reduces the mental preoccupation with food that many people with obesity experience. People consistently describe it as “food noise” going quiet. The combined effect typically produces weight loss of 10 to 15 percent of body weight over a year or more, though individual results vary widely.
One important reality: weight tends to return after stopping the medication. A large meta-analysis published in the BMJ found that people regain an average of 0.4 kg (just under a pound) per month after discontinuation. Cardiometabolic markers like blood sugar and cholesterol are projected to return to their pre-treatment levels within about 1.4 years. This is why most clinicians treat semaglutide as a long-term or indefinite medication rather than a short course.
Cardiovascular Protection
Beyond blood sugar and weight, semaglutide has proven benefits for the heart. The SELECT trial, one of the largest cardiovascular outcome studies of a weight-loss drug, enrolled patients who were overweight or obese and already had established cardiovascular disease but not diabetes. Semaglutide reduced the risk of major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) by 20 percent compared to placebo.
Based on those results, the FDA approved Wegovy as the first weight management drug specifically indicated to reduce the risk of serious heart problems in adults with cardiovascular disease and obesity or overweight. This was a landmark decision because it shifted the conversation around these drugs from cosmetic weight loss to genuine disease prevention.
Kidney Disease Protection
The FLOW trial, the first large randomized study to test a GLP-1 drug specifically on kidney outcomes, found that semaglutide reduced the risk of kidney disease progression by 24 percent in people with type 2 diabetes and chronic kidney disease. The trial was stopped early because the benefit was so clear. Patients on semaglutide also lost kidney function more slowly, preserving about 1.16 mL/min of filtration capacity per year compared to placebo. That may sound small, but over years it can mean the difference between stable kidney function and dialysis.
For patients with both type 2 diabetes and kidney disease, this is now a specific part of prescribing guidance. Novo Nordisk’s dosing information recommends increasing to the 1 mg maintenance dose after at least four weeks on 0.5 mg for this population.
Emerging Off-Label Uses
Researchers are investigating semaglutide for conditions that go well beyond its approved indications. Two areas generating particular interest are polycystic ovary syndrome (PCOS) and addiction.
PCOS, which affects hormone balance and fertility in women, is closely linked to insulin resistance. Because semaglutide improves insulin sensitivity and promotes weight loss, clinicians hope it can reduce the elevated androgen levels that drive many PCOS symptoms. A clinical trial at the University of Hull is currently testing semaglutide’s effects on weight, androgen levels, and quality of life in women with the condition.
The addiction connection emerged from an unexpected direction. People taking GLP-1 drugs for diabetes began spontaneously reporting that they were drinking less alcohol. Scientists believe semaglutide dampens the brain’s reward response not just to food but to other pleasurable substances as well. Researchers at the University of North Carolina and elsewhere are now designing trials to formally test whether the drug can help with alcohol and other substance use disorders.
Common Side Effects
The most frequent side effects are gastrointestinal. Nausea affects 15 to 23 percent of patients and is the single most common complaint. Diarrhea occurs in 8 to 14 percent. Vomiting is also reported, though less consistently quantified in trial data. These symptoms are most likely during the first few weeks and during dose increases, which is exactly why the titration schedule starts low and climbs gradually.
For most people, the nausea fades as the body adjusts. Eating smaller meals, avoiding high-fat foods, and not lying down immediately after eating can help during the adjustment period. A smaller number of patients experience more persistent GI symptoms that require dose adjustments or, occasionally, discontinuation.